Home

סדר פעולות עליונות איש teva pharmaceuticals financial calenar צמיג אהוב בדוק

FDA swats back Teva, MedinCell's long-acting schizophrenia drug application  | Fierce Pharma
FDA swats back Teva, MedinCell's long-acting schizophrenia drug application | Fierce Pharma

Sell Teva Pharmaceutical due to increasing generic drugs competition:  Credit Suisse
Sell Teva Pharmaceutical due to increasing generic drugs competition: Credit Suisse

Teva Reports Third Quarter 2020 Financial Results | Business Wire
Teva Reports Third Quarter 2020 Financial Results | Business Wire

Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA)  | Seeking Alpha
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA) | Seeking Alpha

Teva Reports Second Quarter 2021 Financial Results | Business Wire
Teva Reports Second Quarter 2021 Financial Results | Business Wire

TEVA PHARMACEUTICAL INDUSTRIES LIMITED : TEVA Stock Price | IL0006290147 |  MarketScreener
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : TEVA Stock Price | IL0006290147 | MarketScreener

Teva Reports Fourth Quarter and Full Year 2021 Financial Results | Business  Wire
Teva Reports Fourth Quarter and Full Year 2021 Financial Results | Business Wire

Teva Pharmaceutical Rallies, So Let's Adjust Our Bullish Strategy -  RealMoney
Teva Pharmaceutical Rallies, So Let's Adjust Our Bullish Strategy - RealMoney

Teva Pharmaceutical Industries Limited 2022 Q3 - Results - Earnings Call  Presentation (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Industries Limited 2022 Q3 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha

Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha
Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha

Teva Reports First Quarter 2020 Financial Results | Business Wire
Teva Reports First Quarter 2020 Financial Results | Business Wire

Teva to pay up to $4.2 billion in U.S. to settle opioid claims |  MarketScreener
Teva to pay up to $4.2 billion in U.S. to settle opioid claims | MarketScreener

Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg

Definitive Proxy Statement
Definitive Proxy Statement

Teva beats first-quarter expectations but still has the same old problems -  MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch

Here's Why Teva Shares are Trending Higher Today - TipRanks.com
Here's Why Teva Shares are Trending Higher Today - TipRanks.com

Teva Faces Rocky Path to Recovery After Debt | Fortune
Teva Faces Rocky Path to Recovery After Debt | Fortune

Teva Pharmaceutical: What To Expect In 2023 With New CEO (NYSE:TEVA) |  Seeking Alpha
Teva Pharmaceutical: What To Expect In 2023 With New CEO (NYSE:TEVA) | Seeking Alpha

Teva selects North Jersey site for its new North American headquarters. -  Philadelphia Business Journal
Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal

TEVA Stock Price and Chart — NYSE:TEVA — TradingView
TEVA Stock Price and Chart — NYSE:TEVA — TradingView

Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha

Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect -  MarketWatch
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch

Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) |  Seeking Alpha
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha

Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week (NYSE: TEVA) | Seeking Alpha
Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week (NYSE: TEVA) | Seeking Alpha